Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Paz

Showing results (241-250 of 258) with videos related to

Pageof 26
Sort By:
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
European Urology|December 13, 2002
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)J R Germà-Lluch, X Garcia del Muro, P Maroto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 26, 2016
A consensus statement on the gender perspective in lung cancerD Isla, M Majem, N Viñolas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
ESMO Open|December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European expertsP M Putora, G F Fischer, M Früh, et al.
Pageof 26

Showing results (241-250 of 258) with videos related to

Sort By:
Pageof 26
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
European Urology|December 13, 2002
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)J R Germà-Lluch, X Garcia del Muro, P Maroto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 26, 2016
A consensus statement on the gender perspective in lung cancerD Isla, M Majem, N Viñolas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
ESMO Open|December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trialF Griesinger, G Curigliano, M Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European expertsP M Putora, G F Fischer, M Früh, et al.
Pageof 26